Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $283,039.64 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the completion of the sale, the chief financial officer now directly owns 118,077 shares of the company's stock, valued at approximately $2,885,801.88. This represents a 8.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total value of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $0.29 during trading on Tuesday, hitting $26.19. The company had a trading volume of 7,147,952 shares, compared to its average volume of 9,539,847. The stock has a 50 day simple moving average of $27.31 and a 200 day simple moving average of $21.68. The firm has a market capitalization of $5.72 billion, a P/E ratio of 59.52 and a beta of 1.31. Hims & Hers Health, Inc. has a 12 month low of $8.14 and a 12 month high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.04) EPS. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Hims & Hers Health

Large investors have recently added to or reduced their stakes in the company. Quest Partners LLC boosted its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company's stock worth $81,000 after purchasing an additional 807 shares during the period. CWM LLC boosted its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after purchasing an additional 1,054 shares during the period. Cadent Capital Advisors LLC boosted its holdings in Hims & Hers Health by 1.5% during the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company's stock valued at $1,745,000 after acquiring an additional 1,060 shares during the period. Victory Capital Management Inc. boosted its holdings in Hims & Hers Health by 6.6% during the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company's stock valued at $393,000 after acquiring an additional 1,212 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its holdings in Hims & Hers Health by 5.8% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company's stock valued at $622,000 after acquiring an additional 1,864 shares during the period. Institutional investors own 63.52% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Needham & Company LLC upped their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a report on Monday, January 6th. Morgan Stanley assumed coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an "overweight" rating and a $42.00 price objective for the company. Citigroup downgraded Hims & Hers Health from a "neutral" rating to a "sell" rating and increased their price objective for the stock from $24.00 to $25.00 in a report on Friday. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.